Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine.
Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine.
复制标题
第二剂 BNT162b2 疫苗后 100 至 200 天，抗 SARS-CoV-2 尖峰抗体水平减弱。
DOI：
10.3390/vaccines10020177
复制
发表时间：
2022-01-24
期刊：
影响因子：
7.8
通讯作者：
Tomonaga K
中科院分区：
文献类型：
--
作者：
Matsunaga H;Takeuchi H;Oba Y;Fujimi S;Honda T;Tomonaga K
对日本444名接种BNT162b2疫苗的医院工作人员在接种第二剂BNT162b2疫苗后94-109天和199-212天进行了抗SARS-CoV-2抗体检测，以评价我们队列中抗体应答的强度和持续时间。在未感染的受试者中，第二次接种后199-212d的抗S抗体水平较第二次接种后第94-109d的水平显著下降(中位数分别为830AU/mL和2425AU/mL；p<；0.001)。在两个测试期之间，感染的参与者的下降率低于未感染的参与者(中位数分别为47.7%和33.9%；p<；0.001)。女性抗S抗体水平显著高于女性(中位数：女性，2546AU/毫升；男性，2041AU/毫升；p=0.002)。接种后女性最高体温高于男性(中位数：女性，37.4C；男性：37.1C；p=0.044)。年龄较大的男性往往抗体水平较低。总而言之，抗S抗体对BNT162b2疫苗的应答持续时间很短，尤其是在男性。根据雅培公司的SARS-CoV-2Ig G II Quant(雅培)，抗S抗体水平为1000AU/mL或更低可能表明对Delta变异株的预防不足，大多数参与者似乎在接种疫苗200天后失去了保护作用。
Anti-SARS-CoV-2 antibodies of 444 vaccinated hospital employees in Japan were measured 94–109 days and 199–212 days after receiving the second BNT162b2 vaccine dose to evaluate the intensity and duration of antibody response in our own cohort. Among uninfected participants, anti-S antibody levels were greatly decreased 199–212 days after the second vaccination compared to the levels measured 94–109 days after the second vaccination (median levels: 830 AU/mL and 2425 AU/mL, respectively; p < 0.001). The rate of decrease between the two testing periods was lower in infected participants than in uninfected participants (median: 47.7% and 33.9%, respectively; p < 0.001). Anti-S antibody levels were significantly higher in females (median: females, 2546 AU/mL; males, 2041 AU/mL; p = 0.002 during the first test period). The peak body temperature after vaccination was higher in females than in males (median: females, 37.4 °C; males: 37.1 °C; p = 0.044). Older males tended to have lower antibody levels. In conclusion, the duration of the anti-S antibody response to the BNT162b2 vaccine was short-lived, particularly in males. Anti-S antibody levels of 1000 AU/mL or lower according to SARS-CoV-2 IgG II Quant (Abbott) might indicate insufficient prevention against the delta variant, and the majority of participants appeared to have lost their protection 200 days after vaccination.
登录
查看更多内容
影响因子：
6.7
作者：
Lombardi A;Consonni D;Oggioni M;Bono P;Uceda Renteria S;Piatti A;Pesatori AC;Castaldi S;Muscatello A;Riboldi L;Ceriotti F;Bandera A;Gori A
通讯作者：
Gori A
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
15.1
作者：
Pellini R;Venuti A;Pimpinelli F;Abril E;Blandino G;Campo F;Conti L;De Virgilio A;De Marco F;Di Domenico EG;Di Bella O;Di Martino S;Ensoli F;Giannarelli D;Mandoj C;Manciocco V;Marchesi P;Mazzola F;Moretto S;Petruzzi G;Petrone F;Pichi B;Pontone M;Zocchi J;Vidiri A;Vujovic B;Piaggio G;Morrone A;Ciliberto G
通讯作者：
Ciliberto G
影响因子：
2.7
作者：
Jung K;Shin S;Nam M;Hong YJ;Roh EY;Park KU;Song EY
通讯作者：
Song EY